Insights

Strategic Partnerships Olaris has attracted strategic investments from Bruker and Labcorp, indicating validated interest from established life science players. This suggests opportunities for co-development, data collaboration, or expanded diagnostics commercialization through these or similar partners.

Clinical Adoption Recent and upcoming presentations at major transplant congresses and the launch of myOLARIS-KTdx demonstrate active clinical validation and demand in transplantation and nephrology. Sales opportunities exist in hospitals and transplant centers seeking non-invasive metabolomics-based diagnostics.

Noninvasive Diagnostics Product focus on non-invasive urine-based and metabolomics-enabled tests positions Olaris for payer-friendly, patient-friendly diagnostics. This can be leveraged to approach nephrology, transplant, and neurology segments seeking reduced invasive testing and improved monitoring.

Market Expansion With indications spanning oncology, organ transplant, and neurodegeneration, there are cross-indication upsell opportunities for existing customers and expansion targets within large biopharma portfolios looking for companion diagnostics and treatment optimization.

Data-Driven Growth Investments from Bruker and Labcorp imply strong data and analytics leverage. There is potential to offer data-driven services, metabolomics analytics platforms, and ML-assisted diagnostic insights to research sites and CROs pursuing precision medicine initiatives.

Similar companies to Olaris, Inc

Olaris, Inc Tech Stack

Olaris, Inc uses 8 technology products and services including Linkedin Insight Tag, Power BI, Wix, and more. Explore Olaris, Inc's tech stack below.

Media & News

Olaris, Inc's Email Address Formats

Olaris, Inc uses at least 2 email formats:
Olaris, Inc Email FormatsExamplePercentage
FLast@myolaris.comJDoe@myolaris.com
88%
FirstLast@myolaris.comJohnDoe@myolaris.com
12%

Frequently Asked Questions

What is Olaris, Inc's phone number?

Minus sign iconPlus sign icon
You can contact Olaris, Inc's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Olaris, Inc's official website and social media links?

Minus sign iconPlus sign icon
Olaris, Inc's official website is myolaris.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Olaris, Inc generate?

Minus sign iconPlus sign icon
As of November 2026, Olaris, Inc's annual revenue is estimated to be $10M - $25M.

What is Olaris, Inc's SIC code and NAICS code?

Minus sign iconPlus sign icon
Olaris, Inc's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Olaris, Inc have currently?

Minus sign iconPlus sign icon
As of November 2026, Olaris, Inc has approximately 20 employees across 2 continents, including North America and Europe. Key team members include Chief Business Officer: R. H., Chief Operating Officer & Chief Financial Officer: T. B. and Associate Director, Data Science: G. A. Explore Olaris, Inc's employee directory with LeadIQ.

What industry does Olaris, Inc belong to?

Minus sign iconPlus sign icon
Olaris, Inc operates in the Biotechnology Research industry.

What technology does Olaris, Inc use?

Minus sign iconPlus sign icon
Olaris, Inc's tech stack includes Linkedin Insight Tag, Power BI, Wix, WordPress, Wix eCommerce, Google Cloud, Sentry and Constant Contact.

What is Olaris, Inc's email format?

Minus sign iconPlus sign icon
Olaris, Inc's email format typically follows the pattern of FLast@myolaris.com. Find more Olaris, Inc email formats with LeadIQ.

When was Olaris, Inc founded?

Minus sign iconPlus sign icon
Olaris, Inc was founded in 2013.
Olaris, Inc logo

Olaris, Inc

Biotechnology ResearchMassachusetts, United States11-50 Employees

Olaris, Inc is a biotechnology research company focused on precision medicine. It uses metabolomics and machine learning to develop myOLARIS diagnostic products that aim to tailor treatments and improve patient outcomes. These metabolite-based diagnostics support therapeutic selection, monitoring treatment effectiveness, diagnostic clarity, and target identification across indications including oncology, solid-organ transplant, and neurodegeneration. 

Based in Framingham, Massachusetts, the company operates with a small-to-mid-sized team in the biotechnology sector. In 2025, Olaris launched myOLARIS-KTdx, a non-invasive urine-based diagnostic that integrates metabolite profiles with clinical data to assess kidney graft injury and immune status.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2013
Employees
11-50

Section iconFunding & Financials

  • $10M - $25M

    Olaris, Inc's revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.